针对阿尔茨海默病的生物活性化合物纳米粒子
Neha Kshirsagar1, Ashwani Patil2,3, Meghraj Suryawanshi4
1Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Inflammopharmacology
|June 5, 2025
概括
生物活性纳米粒子通过向关键病理和克服血脑屏障,为抗击阿尔茨海默病 (AD) 提供了一个有前途的方法. 这些先进的传递系统显示出改善痴呆症治疗的潜力.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是痴呆的主要原因,其特征是粉样质斑块和神经纤维状结.
- 目前的治疗方法可以控制症状,但不能改变疾病的进展.
- 血脑屏障 (BBB) 限制了传统疗法的疗效.
研究的目的:
- 探索生物活性纳米粒子在阿尔茨海默病治疗中的潜力.
- 为了研究纳米粒子如何克服血脑屏障.
- 审查针对AD病理的纳米粒子系统.
主要方法:
- 对AD.提供纳米粒子传递系统的现有文献的审查.
- 分析穿越血脑屏障的机制 (例如,细胞转移,细胞介导运输).
- 评估具有抗炎和抗氧化特性的生物活性成分.
主要成果:
- 生物活性纳米颗粒可以准粉样蛋白聚合和陶过酸化.
- 各种纳米粒子系统在疾病模型中展示了BBB交叉能力.
- 纳米粒子比AD的传统药物输送具有优势.
结论:
- 生物活性纳米粒子通过解决核心病理和改善药物输送,显示出治疗阿尔茨海默病的前景.
- 挑战包括毒性,生物可用性和监管障碍.
- 为了临床应用,需要进一步的研究和开发.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.1K
15:23Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
19.5K
相关概念视频
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
01:26Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686